Abstract:Background: Treponema pallidum particle agglutination assay (TPPA) has been shown to be highly sensitive and specific at detecting treponemal antibodies and is still used as a confirmatory method in many laboratories, in China. In clinical practice, we found that a significant number of TPPA-negative sera were identified when TPPA was used as a confirmatory assay of Architect chemiluminescent microparticle immunoassay (CMIA) screening-reactive sera. Aims: To investigate the consistency between Architect CMIA and TPPA, and analyzed the characterization of TPPA-negative sera following Screening by Architect CMIA. Methods: According to the laboratory syphilis confirmatory testing protocol, a total of 4870 sera were initially tested by Architect CMIA and ELISA, and then the samples which shown positive results were tested by TPPA and rapid plasma reagin tests (RPR). Further analysis using Euroimmun dot-immunoblot (dot-IBT) assay was performed to the CMIA positive and TPPA negative samples. Results: In our cohort, we found that the positive rate of CMIA was 3.1% (149/4870). One hundred and twelve of 112 (75.2%) CMIA-positive sera were TPPA reactive, while 37 (24.8%) sera which were reactive in CMIA were nonreactive by TPPA. Dot-IBT testing was performed on these 37 sera: 8 (21.6%) were dot-IBT positive, 11 (29.7%) were indeterminate and 18 (48.6%) negative. Discussion: In this study, we observed that 18 CMIA-positive sera were false positives confirmed by dot-IBT. But, given the relatively high levels of early syphilis, we consider a small increase in the number of confirmatory tests is worthwhile if we can increase the detection of primary syphilis by 20%. We also found that significant numbers (8/37) of CMIA-positive and TPPA-negative sera were shown by further dot-IBT testing to be positive. The reason why certain sera are negative by TPPA but reactive by CMIA and other syphilis confirmatory assays is not clear, and these initial findings should be further explored. Conclusion: The Architect CMIA is a highly sensitive screening assay for detecting syphilis but it is significantly less specific. Further analysis by TPPA is recommended to confirm the results. We would highlight the fact that in repeatedly screened populations discrepancies between treponemal CMIA and TPPA results are quite prevalent. This seems to be a function of very low levels of syphilis-specific antibodies. Confirmation by immunoblot assay may be useful.

Clinically Analysis of Detecting Syphilis Antibodies by Sandwich ELISA and TPPA

Immunohistochemistry detection of Treponema pallidum and its clinical significance

Comparative study of five analytical methods for screening of antibodies against treponema pallidum

Sensitive and Specific ELISA Coated by TpN15-TpN17-TpN47 Fusion Protein for Detection of Antibodies to Treponema Pallidum.

Clinical Evaluation of Methods for Detection of Treponema Pallidum Infection

Expression of recombinant TpN17 antigen and preliminary application for syphilis diagnosis

[Recombinant Expression of the Fusion Antigen Based on Treponema Pallidum TpN17 and TpN47 Epitope Peptides and Establishment and Application of the Associated ELISA].

Comparison of serological detection effects of ELISA using rTpN17 or rTpN47 of Treponema pallidum as antigen with that of TPHA and TRUST]

[Study on ELISAs with Rtpn17, Rtpn47 and Its Fusion Protein As Antigens in the Detection of Serum Samples from Syphilis Patients].

Significance of PCR in Detection of Immune-Specific Protein of Treponema Pallidum

Development and Application of an Enzyme-linked Immunoassay for Serodiagnosis of Syphilis by Recombinant Trepnoma Palidum Antigens

Consistency Between Treponema pallidum Particle Agglutination Assay and Architect Chemiluminescent Microparticle Immunoassay and Characterization of Inconsistent Samples

The Tradition Algorithm Approach Underestimates the Prevalence of Serodiagnosis of Syphilis in HIV-infected Individuals

Comparison of "Lumipulse anti-Treponema pallidum" and "Architect Syphilis TP" and further examination

Performance Evaluation of CLIA for Treponema Pallidum Specific Antibodies Detection in Comparison with ELISA

Study of Serum Helicobacter Pylori Soluble Antigen

Comparison of ELISA and TRUST on Detecting the Anticardiolipin Antibody Concentrations During the Diagnosis and Treatment of Syphilis

Serological evaluation of recombinant protein antigen Tp0608 for the diagnosis of syphilis

Evaluation of a Treponema IgG ELISA alone and in combination with an IgM ELISA as substitutes for Treponema pallidum particle agglutination (TPPA) as confirmatory tests in a two-tier diagnostic algorithm for diagnosis of syphilis infection

Comparison and evaluation of Abbott chemiluminescent microparticle immunoassay and ChIVD light-initiated chemiluminescent assay in the detection of Treponema pallidum antibody

Screening for Syphilis with Dual Algorithms: Analysis of Discordant and Concordant Serology Results in a Population with a Low Prevalence of Syphilis.